Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Standard view
Full view
of .
Save to My Library
Look up keyword
Like this
0 of .
Results for:
No results containing your search query
P. 1
VVUS Complaint

VVUS Complaint

Ratings: (0)|Views: 162 |Likes:
Published by Allen Yesilevich

More info:

Published by: Allen Yesilevich on Nov 04, 2010
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less





- 1 -
Case No.
12345678910111213141516171819202122232425262728Plaintiff alleges the following against Vivus, Inc. (“Vivus” or the “Company”) and theother Defendants as defined,
19, based upon the investigation of Plaintiff’s counsel,which included a review of United States Securities and Exchange Commission (“SEC”) filingsby Vivus, securities analysts reports and advisories about the Company, press releases issued bythe Company, and media reports about the Company. Plaintiff believes that substantialadditional evidentiary support will exist for the allegations set forth below after a reasonableopportunity for discovery.
This is a securities class action on behalf of all persons who purchased orotherwise acquired the common stock of Vivus between September 9, 2009, and July 15, 2010,inclusive (the “Class Period”), against Vivus and certain of its officers and/or directors forviolations of the Securities Exchange Act of 1934 (the “Exchange Act”).2.
Vivus is a biopharmaceutical company that develops therapies to address obesity,sleep apnea, diabetes, and male sexual health. The Company develops and commercializestherapeutic products for large underserved markets and currently has one FDA-approved drug onthe market, MUSE®, a prescription treatment for erectile dysfunction. The Company also hasseveral investigational product candidates in late stages of clinical development that are focusedon market opportunities in obesity and related morbidities, including sleep apnea and diabetes,and sexual health where the potential worldwide pharmaceutical market could approach billions.The Company’s lead product in clinical development is Qnexa® (“Qnexa” or the “drug”), anexperimental drug that has completed Phase III clinical trials for the treatment of obesity. InDecember 2009, Vivus submitted a New Drug Application (“NDA”) to the Food and DrugAdministration (“FDA”) to have Qnexa approved as an obesity drug. On March 1, 2010, theFDA accepted the NDA filing for review.3.
During the Class Period, Vivus issued materially false and misleading statementsto the investing public regarding Qnexa. Vivus continuously hyped Qnexa’s “remarkablesafety,” and its potential for success via NDA approval, while materially understating the health
- 2 -
Case No.
12345678910111213141516171819202122232425262728risks associated with the drug. As a result of Vivus’s false statements, the Company’s stock traded at artificially inflated prices during the Class Period, reaching a high of $13.68 per shareon May 18, 2010.4.
On July 15, 2010, the Endocrinologic and Metabolic Drugs Advisory Committeeof the FDA (the “FDA Panel”) composed of independent medical experts whoserecommendations carry great weight within the FDA approval process, voted 10 to 6 against theapproval of Qnexa based upon an “overall risk-benefit assessment” for use in obese individualsand certain overweight patients with other health problems such as diabetes or high bloodpressure.
Even some of the panel members who voted “yes” noted that it was “a very fine linebetween a yes and a no vote,” and that they could have voted no.5.
The FDA Panel members who voted “no” cited “serious” and “life-threatening”side effects in Qnexa’s trial data, including birth defects, depression, anxiety, sleep disorders,cognitive disorders, metabolic acidosis (too much acid in the body fluids), and an unknownimpact on the heart as reasons they could not recommend the drug’s approval.6.
The FDA Panel refused to recommend Qnexa as a chronic or “lifetime” drugtherapy because the limited data made it “difficult if not impossible” to weigh the long-termsafety of the drug. Only 56 weeks of safety data were provided from the clinical studies eventhough, if approved, the expected time frame for Qnexa use would be much longer since obesityis a “chronic disease requiring chronic treatment.” According to Dr. Lamont G. Weide, a votingpanel member and endocrinologist at the University of Missouri, Kansas City, “[t]he realquestion is when we look at this drug is how safe it is and for how long because this is likely alifetime therapy.” Dr. Weide also specifically stated, “I feel uncomfortable with a year’s worth
The sixteen voting FDA Panel members included: Dr. Thomas P. Bersot, Dr. David M.Capuzzi, Dr. Allison B. Goldfine, Dr. Abraham Thomas, Dr. Lamont G. Weide, Dr. Elaine H.Morrato, Dr. Sanjay Kaul, Dr. Kenneth D. Burman, Dr. Susan R. Heckbert, Dr. Katherine M.Flegal, Dr. Jessica W. Henderson, Dr. Janet D. Cragan, Ms. Melanie Coffin, Dr. Ed J. Hendricks,Dr. Michael A. Proschan, and Dr. Michael A. Rogawski.

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->